Elliott PJ - Search Results

1

Proteasome inhibition: A novel mechanism to combat asthma.

Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J. Elliott PJ, et al. J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):294-300. doi: 10.1016/s0091-6749(99)70369-6. J Allergy Clin Immunol. 1999. PMID: 10452747

2

Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis.

Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, Lazarus D, McCormack T, Parent L, Stein R, Adams J, Grisham MB. Palombella VJ, et al. Among authors: elliott pj. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15671-6. doi: 10.1073/pnas.95.26.15671. Proc Natl Acad Sci U S A. 1998. PMID: 9861028 Free PMC article.

3

Proteasome inhibition measurements: clinical application.

Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Lightcap ES, et al. Among authors: elliott pj. Clin Chem. 2000 May;46(5):673-83. Clin Chem. 2000. PMID: 10794750

4

Proteasome inhibition: a new strategy in cancer treatment.

Adams J, Palombella VJ, Elliott PJ. Adams J, et al. Among authors: elliott pj. Invest New Drugs. 2000 May;18(2):109-21. doi: 10.1023/a:1006321828515. Invest New Drugs. 2000. PMID: 10857991 Review.

5

Assays for proteasome inhibition.

Elliott PJ, Soucy TA, Pien CS, Adams J, Lightcap ES. Elliott PJ, et al. Methods Mol Med. 2003;85:163-72. doi: 10.1385/1-59259-380-1:163. Methods Mol Med. 2003. PMID: 12710207 Review. No abstract available.

6

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Adams J, et al. Among authors: elliott pj. Cancer Res. 1999 Jun 1;59(11):2615-22. Cancer Res. 1999. PMID: 10363983

7

A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.

Lazarus DD, Destree AT, Mazzola LM, McCormack TA, Dick LR, Xu B, Huang JQ, Pierce JW, Read MA, Coggins MB, Solomon V, Goldberg AL, Brand SJ, Elliott PJ. Lazarus DD, et al. Among authors: elliott pj. Am J Physiol. 1999 Aug;277(2):E332-41. doi: 10.1152/ajpendo.1999.277.2.E332. Am J Physiol. 1999. PMID: 10444430

8

Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome.

Grisham MB, Palombella VJ, Elliott PJ, Conner EM, Brand S, Wong HL, Pien C, Mazzola LM, Destree A, Parent L, Adams J. Grisham MB, et al. Among authors: elliott pj. Methods Enzymol. 1999;300:345-63. doi: 10.1016/s0076-6879(99)00140-8. Methods Enzymol. 1999. PMID: 9919536

9

Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model.

Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH. Zollner TM, et al. Among authors: elliott pj. J Clin Invest. 2002 Mar;109(5):671-9. doi: 10.1172/JCI12736. J Clin Invest. 2002. PMID: 11877475 Free PMC article.

10

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR. Aghajanian C, et al. Among authors: elliott pj. Clin Cancer Res. 2002 Aug;8(8):2505-11. Clin Cancer Res. 2002. PMID: 12171876 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

107 results

Search Page